Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma

被引：10
|
作者：
Fang X. [1 ]
Zhou X. [1 ]
Wang X. [1 ,2 ]
机构：
[1] Department of Hematology, Shandong Provincial Hospital affiliated to Shandong University, 324 Jingwu Road, Jinan
[2] Department of Diagnostics, Shandong University School of Medicine, Jinan
来源：
Biomarker Research | / 1卷 / 1期
基金：
中国国家自然科学基金;
关键词：
Clinical development; NHL; PI3K inhibitors;
D O I：
10.1186/2050-7771-1-30
中图分类号：
学科分类号：
摘要：
Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is extensively explored in cancers. It functions as an important regulator of cell growth, survival and metabolism. Activation of this pathway also predicts poor prognosis in numerous human malignancies. Drugs targeting this signaling pathway have been developed and have shown preliminary clinical activity. Accumulating evidence has highlighted the important role of PI3K in non-Hodgkin lymphoma (NHL), especially in the disease initiation and progression. Therapeutic functions of PI3K inhibitors in NHL have been demonstrated both in vivo and in vitro. This review will summarize recent advances in the activation of PI3K signaling in different types of NHL and the applications of PI3K inhibitors in NHL treatment. © 2013 Fang et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [1] Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin's lymphoma
    Zuo, Wei-Qiong
    Hu, Rong
    Wang, Wan-Li
    Zhu, Yong-Xia
    Xu, Ying
    Yu, Luo-Ting
    Liu, Zhi-Hao
    Wang, Ning-Yu
    BIOORGANIC CHEMISTRY, 2020, 105
  • [2] Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
    Younes, Anas
    Salles, Gilles
    Martinelli, Giovanni
    Bociek, Robert Gregory
    Barrigon, Dolores Caballero
    Barca, Eva Gonzalez
    Turgut, Mehmet
    Gerecitano, John
    Kong, Oliver
    Pisal, Chaitali Babanrao
    Tavorath, Ranjana
    Kim, Won Seog
    HAEMATOLOGICA, 2017, 102 (12) : 2104 - 2112
  • [3] Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
    Brana, Irene
    Siu, Lillian L.
    BMC MEDICINE, 2012, 10
  • [4] Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
    Irene Brana
    Lillian L Siu
    BMC Medicine, 10
  • [5] Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma
    Anders, Penny
    Bhende, Prasanna M.
    Foote, Michael
    Dittmer, Dirk P.
    Park, Steven I.
    Damania, Blossom
    LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 263 - 266
  • [6] Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
    Kong, Dexin
    Yamori, Takao
    CURRENT MEDICINAL CHEMISTRY, 2009, 16 (22) : 2839 - 2854
  • [7] Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin's Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles
    Ali, Abdalrahim M.
    Makki, Alaa A.
    Ibraheem, Walaa
    Abdelrahman, Mohammed
    Osman, Wadah
    Sherif, Asmaa E.
    Ashour, Ahmed
    Ibrahim, Sabrin R. M.
    Ghazawi, Kholoud F.
    Samman, Waad A.
    Alzain, Abdulrahim A.
    MOLECULES, 2023, 28 (05):
  • [8] Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma
    Bei Hu
    Ryan Jacobs
    Nilanjan Ghosh
    Current Hematologic Malignancy Reports, 2018, 13 : 543 - 554
  • [9] Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma
    Hu, Bei
    Jacobs, Ryan
    Ghosh, Nilanjan
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (06) : 543 - 554
  • [10] Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma
    Jahangiri, Sudy
    Friedberg, Jonathan
    Barr, Paul
    EXPERT OPINION ON EMERGING DRUGS, 2014, 19 (03) : 367 - 383
12345